PCYN (Procyon) 1-Year Sharpe Ratio: 0.45 (As of Jul. 07, 2026)


PCYN Procyon Corp PCYN
48 GF Score
Price $0.20
View Full Analysis

What is Procyon 1-Year Sharpe Ratio?

Procyon PCYN 48 1-Year Sharpe Ratio is 0.45 as of Jul. 07, 2026. GuruFocus rates PCYN with a GF Score™ of 48/100.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-07), Procyon's 1-Year Sharpe Ratio is 0.45.

Procyon  (OTCPK:PCYN) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Procyon 1-Year Sharpe Ratio Related Terms

PCYN vs KAYS, YCBD, CBDY: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procyon 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Procyon's 1-Year Sharpe Ratio falls into.


PCYN
48GF Score
Procyon Corp PCYN
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procyon 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.45 mean?
Procyon (PCYN) has a 1-Year Sharpe Ratio of 0.45 as of Jul. 07, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Procyon and its competitors.
Is Procyon's 1-Year Sharpe Ratio too high?
Procyon's current 1-Year Sharpe Ratio is 0.45. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's 1-Year Sharpe Ratio compare to KAYS and YCBD?
Procyon's 1-Year Sharpe Ratio of 0.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Procyon and its competitors. Procyon's current 1-Year Sharpe Ratio is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current 1-Year Sharpe Ratio of 0.45. The current 1-Year Sharpe Ratio is 0.45. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Procyon (PCYN), the current 1-Year Sharpe Ratio is 0.45 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Procyon Business Description

Address 164 Douglas Road East, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score

Get the complete analysis for PCYN

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price